Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean Philippe Jais, Thomas E. Witzig, Corinne Haioun, Carrie A. Thompson, Richard Delarue, Ivana N. Micallef, Fréd́eric Peyrade, William R. Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei I. Syrbu, Olivier Fitoussi, Paul J. Kurtin, Cristine Allmer, Emmanuelle Nicolas-Virelizier, Susan L. Slager, Thomas M. Habermann, Brian K. LinkGilles Salles, Hervé Tilly, James R. Cerhan

Research output: Contribution to journalArticlepeer-review

182 Scopus citations

Fingerprint

Dive into the research topics of 'Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy'. Together they form a unique fingerprint.

Keyphrases

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology